Nucala® (mepolizumab) – New indication
July 29, 2021 - GlaxoSmithKline announced the FDA approval of Nucala (mepolizumab), for the add-on maintenance treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) in adult patients 18 years of age and older with inadequate response to nasal corticosteroids.
Top